NasVax, SciGen to Collaborate on Hepatitis Vaccine

[Guest guest]

Daily International Pharma Alert

Dec. 10, 2007 | Vol. 4 No. 240

NasVax, SciGen to Collaborate on Hepatitis Vaccine

Israel’s NasVax has signed an agreement with Singapore’s SciGen to develop and

commercialize a nasally delivered vaccine against hepatitis B.

The vaccine was created by Israeli pharmaceutical company Biotechnology General,

according to Israeli business daily Globes.

Under the agreement, Phase I and IIa trials of the vaccine will be conducted in

Israel and will begin in 2008.

http://fdanews.com/newsletter/article?issueId=11099 & articleId=101994

_________________________________________________________________

Don't get caught with egg on your face. Play Chicktionary!

http://club.live.com/chicktionary.aspx?icid=chick_wlhmtextlink1_dec

[Guest guest]

Daily International Pharma Alert

Dec. 10, 2007 | Vol. 4 No. 240

NasVax, SciGen to Collaborate on Hepatitis Vaccine

Israel’s NasVax has signed an agreement with Singapore’s SciGen to develop and

commercialize a nasally delivered vaccine against hepatitis B.

The vaccine was created by Israeli pharmaceutical company Biotechnology General,

according to Israeli business daily Globes.

Under the agreement, Phase I and IIa trials of the vaccine will be conducted in

Israel and will begin in 2008.

http://fdanews.com/newsletter/article?issueId=11099 & articleId=101994

_________________________________________________________________

Don't get caught with egg on your face. Play Chicktionary!

http://club.live.com/chicktionary.aspx?icid=chick_wlhmtextlink1_dec

[Guest guest]

Daily International Pharma Alert

Dec. 10, 2007 | Vol. 4 No. 240

NasVax, SciGen to Collaborate on Hepatitis Vaccine

Israel’s NasVax has signed an agreement with Singapore’s SciGen to develop and

commercialize a nasally delivered vaccine against hepatitis B.

The vaccine was created by Israeli pharmaceutical company Biotechnology General,

according to Israeli business daily Globes.

Under the agreement, Phase I and IIa trials of the vaccine will be conducted in

Israel and will begin in 2008.

http://fdanews.com/newsletter/article?issueId=11099 & articleId=101994

_________________________________________________________________

Don't get caught with egg on your face. Play Chicktionary!

http://club.live.com/chicktionary.aspx?icid=chick_wlhmtextlink1_dec

[Guest guest]

Daily International Pharma Alert

Dec. 10, 2007 | Vol. 4 No. 240

NasVax, SciGen to Collaborate on Hepatitis Vaccine

Israel’s NasVax has signed an agreement with Singapore’s SciGen to develop and

commercialize a nasally delivered vaccine against hepatitis B.

The vaccine was created by Israeli pharmaceutical company Biotechnology General,

according to Israeli business daily Globes.

Under the agreement, Phase I and IIa trials of the vaccine will be conducted in

Israel and will begin in 2008.

http://fdanews.com/newsletter/article?issueId=11099 & articleId=101994

_________________________________________________________________

Don't get caught with egg on your face. Play Chicktionary!

http://club.live.com/chicktionary.aspx?icid=chick_wlhmtextlink1_dec